Lumateperone (ITI-007)

DRUG2 trials

Sponsors

Intra-Cellular Therapies, Inc., CSTrials Inc.

Conditions

Bipolar DepressionStuttering, Adult

Phase 2

Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder

RecruitingNCT07734103

CSTrials Inc.Stuttering, Adult

Start: 2026-04-18End: 2027-10-31Target: 24Updated: 2026-07-29

Phase 3

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

CompletedNCT02600507

Intra-Cellular Therapies, Inc.Bipolar Depression

Start: 2016-03-07End: 2020-07-02Updated: 2023-05-17

Related Papers

Long-Term Lumateperone Treatment in Bipolar Disorder: Six-Month Open-Label Extension Study

CNS Spectrums2023-04-014 citations

Adjunctive lumateperone (<scp>ITI</scp>‐007) in the treatment of bipolar depression: Results from a randomized <scp>placebo‐controlled</scp> clinical trial

Bipolar Disorders2023-02-1324 citations